U.S. Markets closed

Voyageur Pharmaceuticals Ltd. (VM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1550-0.0100 (-6.06%)
At close: 3:29PM EDT

Voyageur Pharmaceuticals Ltd.

339–50th Avenue SE
Suite 255
Calgary, AB T2G 2B3
Canada
587-779-6166
http://voyageurpharmaceuticals.ca

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Brent WillisPres, CEO & Director62.5kN/A1971
Mr. Bradley Craig Willis P.Eng.Founder, COO & VP of Exploration62.5kN/A1971
Mr. Ronald Robert LoveChief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the industrial barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is based in Calgary, Canada.

Corporate Governance

Voyageur Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.